Home > Resources > Videos > Exploring the Human Genome

Exploring the Human Genome

Discover how advances in genomics are transforming medtech for healthcare with this online genomics course.

Spotlight

APEIRON Biologics

Apeiron Biologics AG is a privately financed Biotech company in Vienna, Austria. The company currently employs around 25 people and has a strong focus on immunological approaches to treat cancer. In 2010, Apeiron out-licensed itslead project (a recombinant enzyme for the treatment of Acute Respiratory Distress Syndrome and other diseases) to GSK in a deal potentially worth €236 million. Subsequently, Apeiron in-licensed several clinical projects (a liposomal formulation of SOD, a fusion protein and a monoclonal antibody against neuroblastoma) to complement its innovative in-house projects

OTHER VIDEOS

Image analysis software for true ultra high content data on the MACSima™ Imaging System

video | July 28, 2023

Qi Tissue Image Analysis Software for the MACSima™ Imaging Platform is the key to unlocking staggering analytical ability with ultra high content imaging data generated on the revolutionary new MACSima Imaging Platform....

Watch Now

Bioprinting Living Cells: The Next Frontier in Biotechnology Technology

video | July 30, 2023

Bioprinting with living human cells is transforming healthcare as we know it. From Slurpee-like substances to molding 3D tissues, explore the cutting-edge world of 3D bioprinting. Dr. Mark Skylar-Scott from Stanford University discusses the fascinating realm of 3D bioprinting, a groundbreaking approach that goes beyond traditional plastic printing....

Watch Now

VIA Thaw™ automated dry thawer

video | May 9, 2023

VIA Thaw™ dry automated thawers give you the confidence to reliably recover cryopreserved cellular products. VIA Thaw™ L1000 intended for research or manufacturing use only is an automated dry thawer that you can use for controlled, consistent thawing of cellular products in cryobags....

Watch Now

NeatCell C-Pro application software for the Sepax™ C-Pro instrument

video | May 9, 2023

Meet the NeatCell C-Pro application. It automates the mononuclear cell fraction enrichment from diverse cellular products, and is designed for use with a density-gradient medium like Ficoll-Paque media with the Sepax C-Pro instrument and CT-90.1 single-use kit....

Watch Now

Image analysis software for true ultra high content data on the MACSima™ Imaging System

video | July 28, 2023

Qi Tissue Image Analysis Software for the MACSima™ Imaging Platform is the key to unlocking staggering analytical ability with ultra high content imaging data generated on the revolutionary new MACSima Imaging Platform....

Watch Now

Bioprinting Living Cells: The Next Frontier in Biotechnology Technology

video | July 30, 2023

Bioprinting with living human cells is transforming healthcare as we know it. From Slurpee-like substances to molding 3D tissues, explore the cutting-edge world of 3D bioprinting. Dr. Mark Skylar-Scott from Stanford University discusses the fascinating realm of 3D bioprinting, a groundbreaking approach that goes beyond traditional plastic printing....

Watch Now

VIA Thaw™ automated dry thawer

video | May 9, 2023

VIA Thaw™ dry automated thawers give you the confidence to reliably recover cryopreserved cellular products. VIA Thaw™ L1000 intended for research or manufacturing use only is an automated dry thawer that you can use for controlled, consistent thawing of cellular products in cryobags....

Watch Now

NeatCell C-Pro application software for the Sepax™ C-Pro instrument

video | May 9, 2023

Meet the NeatCell C-Pro application. It automates the mononuclear cell fraction enrichment from diverse cellular products, and is designed for use with a density-gradient medium like Ficoll-Paque media with the Sepax C-Pro instrument and CT-90.1 single-use kit....

Watch Now
MORE VIDEOS

Spotlight

APEIRON Biologics

Apeiron Biologics AG is a privately financed Biotech company in Vienna, Austria. The company currently employs around 25 people and has a strong focus on immunological approaches to treat cancer. In 2010, Apeiron out-licensed itslead project (a recombinant enzyme for the treatment of Acute Respiratory Distress Syndrome and other diseases) to GSK in a deal potentially worth €236 million. Subsequently, Apeiron in-licensed several clinical projects (a liposomal formulation of SOD, a fusion protein and a monoclonal antibody against neuroblastoma) to complement its innovative in-house projects

Events